DWA
ALBO

Dorsey Wright & Associates’s Albireo Pharma Inc ALBO Stock Holding History

Dorsey Wright & Associates’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-342
Closed -$11K – 343
2019
Q2 		$11K Buy
+342
New +$11.4K ﹤0.01% 244

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Dorsey Wright & Associates's ALBO Position: Q3 2019 in Review

Dorsey Wright & Associates sold out of Albireo Pharma Inc (ALBO) in Q3 2019, closing a stake of 342 shares — an estimated $11K sold.

Dorsey Wright & Associates first reported a position in ALBO in Q2 2019 and held it in 1 quarter. The position peaked at $11K in Q2 2019. 69 funds tracked by Wall St. Rank hold ALBO as of Q3 2019.

  • Dorsey Wright & Associates reported no remaining Albireo Pharma Inc position as of Q3 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 342 Albireo Pharma Inc shares in Q3 2019, an estimated $11K.
  • Dorsey Wright & Associates first reported a position in Albireo Pharma Inc in Q2 2019 and held it in 1 quarter.
  • Dorsey Wright & Associates's Albireo Pharma Inc position peaked at $11K in Q2 2019.
  • 69 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2019.

Based on Dorsey Wright & Associates's 13F filing for Q3 2019, filed 31 Oct 2019.